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In the ﬁrst decade of the 21st century, we have seen the completion of the human genome project and
marked progress in the human microbiome project. The vast amount of data generated from these efforts
combined with advances in molecular and biomedical technologies have led to the development of a multi-
tude of assays and technologies that may be useful in the diagnosis and management of infectious diseases.
Here, we identify several new assays and technologies that have recently come into clinical use or have poten-
tial for clinical use in the near future. The scope of this review is broad and includes topics such as the serum
marker procalcitonin, gene expression proﬁling, matrix-assisted laser desorption/ionization time-of-ﬂight
mass spectrometry (MALDI-TOF MS), and nucleic acid aptamers. Principles that underlie each assay or tech-
nology, their clinical applications, and potential strengths and limitations are addressed.
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Recent advancements in the ﬁelds of immunology,
molecular biology, bioinformatics, and biomedical en-
gineering have led to the development of new assays
that hold promise for the improved diagnosis and
management of infectious diseases. For the clinician
faced with a patient suffering from possible infection,
a key challenge is knowing when to provide and when
to withhold antimicrobial medications. Initiating effec-
tive antimicrobial therapy early has proven to decrease
morbidity and mortality in severe infection [1, 2],
while the overuse of antimicrobials leads to antimicro-
bial resistance. Antimicrobial resistance is a major
public health threat that has substantial economic
impact on our healthcare system [3, 4]. Judicious use
of antibiotics and effective patient care rely on the
ability to quickly and accurately (1) distinguish infec-
tious from noninfectious etiologies of illness, (2) deﬁne
either the class of pathogen or speciﬁc pathogen re-
sponsible for that illness, (3) assess disease severity, (4)
assess response to therapy, and (5) deﬁne the length of
a treatment course. Here, we review 4 new up-and-
coming assays and technologies that offer improvement
in each of these areas. The intent of this review is to
provide an overview of the principles that underlie each
assay or technique, the clinical or preclinical setting in
which they have been used, and the potential limitations
of each modality. The assays and technologies reviewed
here have either recently come into clinical use or are
expected to come into clinical use in the near future.
Procalcitonin
A novel approach to estimating the likelihood of a
patient having a bacterial infection, and monitoring
response to antimicrobial therapy, is to assess host re-
sponse. Traditionally, this was done by monitoring
clinical signs and symptoms, such as the systemic
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inﬂammatory response syndrome (SIRS). However, these cri-
teria have low sensitivity and/or speciﬁcity for bacterial infec-
tions, and lack standardization in clinical practice. A more
recent approach is to measure serum markers of infection.
One such marker that has generated recent interest is procalci-
tonin (PCT).
PCT is released in multiple body tissues in response to bac-
terial infections via direct stimulation of bacterial cytokines,
such as interleukin1β, tumor necrosis factor α, and interleukin
6 [5]. Interferon γ, a cytokine released in response to viral in-
fections, blocks the upregulation of PCT, resulting in a higher
speciﬁcity of PCT for distinguishing bacterial from viral infec-
tion compared to other inﬂammatory markers such as C-
reactive protein. Quantitatively, PCT helps estimate the risk of
severe bacterial infections or milder viral illnesses [6]. PCT
promptly increases within 6 to 12 hours of bacterial infection.
PCT decreases daily by around 50% if the patient responds to
therapy and the infection is well controlled [7]. Unlike C-
reactive protein and other markers, PCT appears not to be
inﬂuenced by systemic corticosteroid treatments.
Recent research has focused on the impact of PCT testing
on patient management and outcomes. Studies were done in
different clinical settings ranging from low acuity in primary
care, to intermediate acuity in emergency departments and
hospital wards, to high acuity in intensive care units. PCT pro-
tocols have been adapted according to these settings with dif-
ferent PCT cutoff ranges (reviewed in [8]). In low-acuity
settings, PCT was used to guide initial prescription of antimi-
crobials, while in higher-acuity settings PCT was used to guide
duration of treatment: antibiotics were recommended to be
stopped once patients showed clinical response and PCT
dropped to normal values.
Fifteen randomized controlled trials including >4000 pa-
tients have evaluated the efﬁcacy and safety of using PCT for
antibiotic decision making [9]. PCT protocols proved to be ef-
fective in reducing antibiotic exposure compared to standard
groups in all trials. PCT guidance lowered antibiotic prescrip-
tion rates by 65% in primary care patients, 35% in the emer-
gency department setting, and almost 30% in the critical care
setting (see detailed results in Table 1). Such a strategy has
also been found cost-effective in a North American healthcare
system assuming PCT costs of around CA$40 [10]. No other
biomarker has been evaluated within such rigorous trial
designs. Still, concern about low adherence to PCT protocols
remains, especially in critical care settings. Studies from “real
life” have shown that adherence is a crucial factor when such
protocols are implemented [11, 12]. Also, studies that have
used PCT to escalate antibiotic therapy when values did not
drop were disappointing [13].
Traditional culture methods, such as blood cultures, focus
on identiﬁcation and characterization of pathogens. Yet, they
have low sensitivity and, thus, if negative, may not inﬂuence
clinical decision making. A blood marker, such as PCT, mir-
rors a patient’s response to infection and indirectly the seve-
rity of infection. The marker may not be able to identify the
etiology of infection, but the likelihood of a relevant bacterial
infection increases with increasing marker levels. The marker
then may help rule out infection and provides information
about patient recovery. With new microbiological methods be-
coming available that rapidly identify microorganisms with
higher sensitivity as discussed below, PCT may help to in-
crease speciﬁcity by providing information about the “rele-
vance” of microbiological results in individual patients.
Gene Expression Proﬁling of Peripheral Blood Leukocytes
Gene expression proﬁling of peripheral blood cells is an emerg-
ing strategy for diagnosing and monitoring infection. Like pro-
calcitonin, gene expression proﬁles use host response to
pathogens as a means of diagnosing infection rather than direct
pathogen detection. Unlike PCT, gene expression proﬁles simul-
taneously measure the expression of a large number of genes to
generate a snapshot of host immune cell function. Pattern-
recognition receptors on immune cells are activated by different
pathogen-derived ligands. This results in the initiation of dis-
tinct sets of transcriptional programs. The resultant pattern of
gene expression may be viewed as a transcriptional signature
that represents or is diagnostic of a speciﬁc pathogen.
The ﬁrst step in gene expression proﬁling requires isolation
of RNA transcripts from cells of interest, most commonly pe-
ripheral blood cells. Microarrays are the most frequently used
gene expression platform in clinical work and allow for analy-
sis on a genome-wide scale. A microarray is a solid support to
which an array of oligonucleotide probes representing speciﬁc
gene coding regions is afﬁxed. Isolated RNA is typically tran-
scribed into complementary DNA (cDNA), ﬂuorescently
labeled and hybridized to the array. The strength of the ﬂuo-
rescent signal generated from each probe represents the rela-
tive abundance of the corresponding RNA transcript. The
differential expression of genes between 2 states, such as infec-
tion versus health, or bacterial versus viral infection, can then
be compared. While microarrays have been the mainstay for
gene expression proﬁling in the recent past, they may soon be
superseded by newer technologies such as high-throughput
cDNA sequencing, which has a greater dynamic range and
also provides sequence information on each RNA transcript
(reviewed in [14]) or by direct RNA sequencing, which elimi-
nates some of the artifact introduced with cDNA synthesis
(reviewed in [14, 15]).
Some of the initial work using gene expression proﬁling of
peripheral blood leukocytes to discriminate bacterial from
viral infections was recently described [16, 17]. Using genome-
wide expression proﬁles obtained from 131 pediatric patients
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with acute infections, Ramilo et al [16] identiﬁed a set of 35
genes that distinguished inﬂuenza A infection from bacterial
infections with 87%–95% accuracy. Using sets of either 30 or
45 genes, they were able to differentiate Escherichia coli, Staph-
ylococcus aureus, and Streptococcus pneumoniae infections
with 83%–95% accuracy. On the basis of this data, they gener-
ated a microarray of 137 genes that had the greatest power to
discriminate among pathogens. This array was able to distin-
guish the expression proﬁles of 27 patients with acute respira-
tory infection compared to 7 healthy controls. In subsequent
work, Zaas et al developed a 30-gene transcriptional signature
of acute respiratory viral infections in adults experimentally
infected with common respiratory viruses [17]. Using this 30-
gene signature, reanalysis of the pediatric datasets from
Ramilo’s work was able to distinguish children with viral in-
fection from healthy controls with 100% accuracy. Inﬂuenza A
was distinguished from any bacterial infection with 80% accu-
racy and inﬂuenza A from streptococcal pneumonia infection
with 93% accuracy. The work of these 2 groups also highlights
a shortcoming of gene expression proﬁling. In the setting of
polymicrobial or mixed viral and bacterial infections, indis-
tinct proﬁles can be generated, thus limiting the utility of this
potential new diagnostic.
Multiple groups have used gene expression proﬁling of pe-
ripheral blood leukocytes to distinguish sepsis from sterile
SIRS. Tang et al generated a 50-gene transcriptional proﬁle of
sepsis that distinguished sepsis from sterile SIRS with 88%–
91% accuracy [18]. Notably, the majority of these studies have
shown an upregulation of pattern recognition receptors such
as Toll-like receptors and CD14, as well as signal transduction
pathways including nuclear factor kappa B, mitogen-activated
protein kinase, and Janus kinase, that are involved in coordi-
nating host immune responses [19]. By contrast, the expres-
sion levels of inﬂammatory cytokines such as tumor necrosis
factor and members of the interleukin family, vary between
studies and no consistent pattern has been discerned [19].
This interstudy variability highlights some of the challenges in
bringing gene expression proﬁling into the clinical arena.
Many of these studies are limited by small sample size and,
ultimately, large, prospective clinical trials will be needed for
validation of transcriptional proﬁles in diagnosing and moni-
toring infection. Signiﬁcant challenges in standardizing tech-
nique and data analysis also remain before expression
proﬁling in infectious diseases is brought into clinical use.
However, similar challenges have been overcome in the ﬁelds
of oncology, where transcriptional proﬁling is used to help
Table 1. Efﬁcacy and Safety of Procalcitonin Protocols in Previous Randomized Controlled Trials
Efficacy Safety
Initiation of
Antibiotics, %
Duration of Antibiotics,
Median (IQR)
Total Antibiotic
Exposure, Median (IQR)
Mortality,
Adjusted OR
(95% CI)
P
Value
Treatment
Failurea,
Adjusted OR
(95% CI)
P
Value
Setting
Overall 64% vs 84% 7 (4–10) vs 10 (7–13) 4 (0–8) vs 8 (5–12) 0.94 (.71–1.23) .754 0.82 (.71–.97) .02
Primary care 23% vs 63% 7 (5–8) vs 7 (6–8) 0 (0–0) vs 6 (0–7) … … 0.95 (.73–1.24) .687
Emergency
department
73% vs 88% 7 (4–10) vs 10 (7–12) 5 (0–8) vs 9 (5–12) 1.03 (.7–1.5) .895 0.76 (.61–.95) .01
ICU 100% vs 100% 8 (5–15) vs 12 (8–18) 8 (5–15) vs 12 (8–18) 0.84 (.54–1.31) .443
Diagnoses
Upper ARI 15% vs 48% 7 (5–8) vs 7 (6–7) 0 (0–0) vs 0 (0–7) … … 0.95 (.73–1.24) .687
Community-
acquired
pneumonia
90% vs 99% 7 (5–10) vs 10 (8–14) 6 (4–10) vs 10 (8–14) 0.89 (.64–1.23) .471 0.77 (.62–.96) .02
Ventilator-
associated
pneumonia
99% vs 100% 11 (6–17) vs 14 (9–19.5) 11 (6–17) vs 14 (9–19.5) 0.69 (.25–1.94) .486 0.69 (.25–1.94) .486
Acute
bronchitis
24% vs 66% 7 (4–9) vs 7 (5–8) 0 (0–0) vs 5 (0–7) … … 1.09 (.70–1.70) .71
Exacerbation
of COPD
48% vs 73% 6 (3–9) vs 8 (6–10) 0 (0–6) vs 7 (0–10) 1.15 (.43–3.09) .774 0.75 (.46–1.22) .25
Abbreviations: ARI, acute respiratory infection; COPD, chronic pulmonary obstructive disease; ICU, intensive care unit.
a Treatment failure was defined according to clinical setting: primary care (death, hospitalization, ARI-specific complications, recurrent or worsening infection, and
discomfort at 30 days), emergency department (mortality, ICU admission, rehospitalization, complications, recurrent or worsening infection within 30 days),
intensive care unit (all-cause mortality within 30 days).
Source: Adapted from Schuetz et al [9].
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predict outcomes in breast cancer patients [20, 21]. As the
technology improves, cost declines, and knowledge of leuko-
cyte biology grows, it becomes increasingly likely that periph-
eral blood transcriptional proﬁling will become a clinically
valuable diagnostic.
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass
Spectrometry
Matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry (MALDI-TOF MS), a method with broad appli-
cations in biochemistry, proteomics, and polymer chemistry,
has recently been adapted for the identiﬁcation of whole mi-
croorganisms [22–26]. The development of user-friendly, inte-
grated commercial MALDI-TOF MS platforms has brought
this technology into many European, and some US, clinical
microbiology laboratories, where it has been used to identify
organisms from colonies on solid media as well as directly
from positive blood and urine cultures [22, 27–31]. The tech-
nique has proved capable of accurately identifying mycobacte-
ria and nonfermenting bacteria, organisms that have posed
difﬁculties for conventional methods [33, 34]. Although the
US Food and Drug Administration (FDA) has yet to approve
any commercial MALDI-TOF MS system for clinical use, this
technology offers improved turnaround time and will comple-
ment, if not someday supplant, conventional microbiologic
identiﬁcation methods.
MALDI-TOF MS instruments have 3 components: a speci-
men ionization chamber, a time-of-ﬂight mass analyzer, and a
particle detector [32] (Figure 1). Sample preparation is simple,
and involves transferring a portion of an isolated colony onto
a target plate. The deposited colony is then covered with a
chemical matrix and the target plate is loaded into the instru-
ment. The sample-matrix mixture is pulsed by a laser, con-
verting the sample into an ionic gas composed of small
proteins and peptides and other molecules. In the ionization
chamber, positively charged molecules are accelerated through
an electric ﬁeld to velocities that depend on their mass-to-
charge (m/z) ratios. The particles then leave the electric ﬁeld
and enter the time-of-ﬂight mass analyzer. The time it takes a
particle to traverse the mass analyzer (“ﬂight time”) depends
on the velocity developed in the ionization chamber, and
hence, on the m/z ratio. Flight times of individual particles are
measured by a particle detector at the end of the mass analyzer,
and are converted into m/z values that are plotted on a mass
spectrogram. The spectrogram is then compared to a library
by a proprietary algorithm to identify the organism [22].
Principal advantages of MALDI-TOF MS technology in-
clude ease of use, potential to automate, rapid turnaround time,
and low reagent costs [22]. The simplicity of setup and the
ability to run large numbers of isolates per batch readily lend
this technique to high-throughput workﬂow and potential au-
tomation. Once the instrument is loaded, identiﬁcations can
typically be performed in <1 minute, compared with hours to
days for conventional methods. This improvement in turn-
around time may carry substantial clinical beneﬁt. Although
purchase of a MALDI-TOF MS instrument involves a signiﬁ-
cant capital commitment with recurrent annual service con-
tract fees, the reagents and disposables required consist
primarily of target plates, microliter quantities of inexpensive
organic compounds, inoculation loops, and pipette tips with
Figure 1. Schematic diagram of a matrix-assisted laser desorption/ionization time-of-ﬂight mass spectrometry instrument. The specimen is irradiated
with a laser and converted into an ionic gas in the ionization chamber. Positively charged particles are accelerated in an electric ﬁeld and then traverse
the time-of-ﬂight mass analyzer before colliding with a particle detector. The mass spectrogram is calculated from the measured ﬂight times.
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estimated costs of as little as US$0.10–$0.40 per identiﬁcation
when optimized [22]. In some cases, this operational cost
amounts to one-tenth that of conventional identiﬁcation with
automated biochemical testing platforms.
Multiple studies comparing MALDI-TOF with conventional
techniques have been performed in Europe, where at least 1
commercial MALDI-TOF instrument has CE approval [22]. A
Swiss study compared a MALDI-TOF MS system to conven-
tional methods for the identiﬁcation of 1371 routine bacteria
and yeast isolates in a clinical microbiology laboratory [27].
MALDI-TOF MS provided identiﬁcations for 98.5% of the
isolates, including 93.2% at the species level and 5.3% at the
genus level. Of the species level identiﬁcations, 95.1% matched
conventional identiﬁcations. Eleven percent of discordant
results were due to errors in conventional identiﬁcation, whereas
the remaining 89% of discrepancies were due to errors in
MALDI-TOF identiﬁcation.
Important deﬁciencies in present MALDI-TOF MS plat-
forms include misclassiﬁcation of Shigella as Escherichia coli,
and misclassiﬁcation of Streptococcus pneumoniae as Strepto-
coccus mitis with one instrument [22]. Additionally, present
MALDI-TOF MS instruments have demonstrated poor
performance with polymicrobial samples. In some cases, in-
struments have identiﬁed only 1 organism without indicating
the presence of others [22].
Commercial MALDI-TOF instruments are expected to
evolve rapidly under intense competition for US market share,
pending FDA approval. Additionally, instruments that perform
microbial identiﬁcations by combining polymerase chain reac-
tion with electrospray ionization time-of-ﬂight mass spectro-
metry are likely to enter the competition. While there is room
for improvement, the fast turnaround times, ease of use, and
potential operational cost savings are likely to make mass
spectrometry technology popular in US clinical laboratories in
the near future.
Nucleic Acid Aptamers
Nucleic acid aptamers are short, single-stranded oligonucleo-
tides that bind to a broad range of targets with high afﬁnity and
speciﬁcity. The use of oligonucleotides as afﬁnity probes for
proteins or other molecules was ﬁrst described by Tuerk and
Gold [35] and Ellington and Szostak [36] in 1990. A nucleic
acid aptamer may be composed of either DNA or RNA and is
typically 15–90 bases in length. Aptamers with high afﬁnity and
Figure 2. In systematic evolution of ligands by exponential enrichment (SELEX), a large pool of random oligonucleotides is incubated with a target
molecule. Upon binding, the short nucleic acid sequence folds into a 3-dimensional structure that binds to its target. Bound nucleic acids are then
eluted and ampliﬁed by polymerase chain reaction. This cycle is repeated until oligonucleotides with suitably high speciﬁcity and binding afﬁnity are
isolated [47]. Through this process aptamers with low picomolar to nanomolar dissociation constants (Kd) can be obtained [48]. The SELEX process
involves 5 main steps: (1) incubation of a random pool of nucleic acids with a target molecule or cell; (2) separating bound nucleic acids from unbound
nucleic acids; (3) eluting the bound nucleic acid from the target; (4) amplifying the eluted nucleic acids to generate a reﬁned pool of nucleic acids; and
(5) using amplicons as new nucleic acid pools in subsequent rounds of selection. This process is repeated until “aptamers” with high speciﬁcity and
afﬁnity for the target are isolated. Abbreviations: PCR, polymerase chain reaction; SELEX, systematic evolution of ligands by exponential enrichment.
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speciﬁcity for their targets are selected in an iterative process
called systematic evolution of ligands by exponential enrichment
(SELEX) [35–37] (Figure 2). The binding afﬁnity of aptamers
rival and often surpass that of antibodies. Aptamers also have
great discriminatory power. As an example, an aptamer devel-
oped for the detection of theophylline is 14 000-fold more spe-
ciﬁc for theophylline than caffeine, a molecule that differs from
theophylline by the presence of a single methyl group [38].
Conventionally, nucleic acid aptamers were selected for pu-
riﬁed target molecules. In 2008, Hamula et al modiﬁed the
SELEX process using live bacterial cells in suspension as
targets [39]. Using this technique, this group was able to
develop an aptamer to Lactobacillus acidophilus that distin-
guished this bacterium from other bacterial and fungal genera.
Their work highlights one of the major strengths of aptamer
technology—namely, that a speciﬁc protein target does not
need to be isolated prior to selection. The use of whole bacte-
rium as a target also allows for the detection selection of ap-
tamers that target proteins in their native conformation.
Subsequently, this group used the 10 most prevalent strains of
group A streptococcus as targets in the SELEX process and
were able to derive aptamers with high afﬁnity and speciﬁcity
compared to other streptococcal species [40]. Whole cell
SELEX has also been used to derive aptamers capable of dis-
tinguishing Escherichia coli O157:H7 from a nonpathogenic
strain of Escherichia coli [41]. This technique has also been
used in vitro to identify a panel of 5 aptamers capable of distin-
guishing Staphylococcus aureus from Staphylococcus epidermidis.
The same aptamer panel was then used to identify Staphylococ-
cus aureus in the ﬂuid of an infected wound [42]. Similar whole
bacterium SELEX methods have been used to develop aptamers
for Campylobacter jejuni [43], Vibrio parahaemolyticus [44],
and multiple Salmonella species [45, 46]. Further reﬁnement is
needed before aptamer-based assays for pathogen detection
come into clinical use; however, given their high speciﬁcity and
the ease with which they can be modiﬁed, aptamers may
become ideal reagents for use in point-of-care tests.
Because of their high discriminatory power, aptamers have
potential for genotyping and serotyping viruses. Gopinath et al
developed an RNA aptamer capable of distinguishing a single-
subtype H3N2 inﬂuenza from other inﬂuenza strains, including
other H3N2 viruses [49]. Notably, the aptamer had a 15-fold
greater afﬁnity for the virus when compared to a commercially
available antibody that targeted the same H3N2 strain.
Aptamer manufacturing has many advantages. The oligo-
nucleotides are readily synthesized at scale. They are stable
and robust, with long shelf lives and an ability to withstand
ﬂuctuations in temperature. Aptamers may be easily attached
to a wide variety of detection moieties. But important disad-
vantages include the cost associated with chemical modiﬁca-
tion, the difﬁculty designing aptamers against hydrophobic
nonpolar targets, and the limited library of available commer-
cial aptamers at present. Another potential deﬁciency is that
nucleic acid aptamers can be degraded by serum nucleases that
may limit their applicability in ex vivo diagnostics. Despite these
drawbacks, aptamers are versatile recognition molecules that can
be designed to target virtually any pathogen and are expected to
ﬁnd application in many future diagnostic techniques.
CONCLUSIONS
Antimicrobial resistance is a growing global public health
problem that has substantial impact on morbidity, mortality,
and healthcare costs. Diagnostic uncertainty has been identi-
ﬁed as a driving factor in the misuse and overuse of antimi-
crobials, which can result in selection of resistant microbes.
Diagnostic modalities that help distinguish infectious from
noninfectious causes of illness are much needed. We have
highlighted 2 approaches, one on the early and accurate iden-
tiﬁcation of the pathogen, and the second on the patients’ host
response to the pathogen. This review identiﬁes several novel
technologies that have the potential to dramatically improve
the assessment of patients with presumed infectious diseases,
and help monitor the course of infection and response to
therapy. These technologies are advancing, but additional re-
search and clinical trials are needed to establish their safe, ap-
propriate, and cost-effective use in everyday practice.
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